Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：137
作者：
Soverini, Simona [1 ]
Branford, Susan [2 ,3 ,4 ]
Nicolini, Franck E. [1 ,5 ]
Talpaz, Moshe
Deininger, Michael W. N. [6 ]
Martinelli, Giovanni [1 ]
Mueller, Martin C. [7 ]
Radich, Jerald P. [8 ]
Shah, Neil P. [9 ]
机构：
[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia
[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France
[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期
关键词：
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;
D O I：
10.1016/j.leukres.2013.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 20
页数：11
相关论文
共 50 条
  • [41] Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
    De, Surya K.
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (03) : 424 - 433
  • [42] Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
    Zabriskie, M. S.
    Vellore, N. A.
    Gantz, K. C.
    Deininger, M. W.
    O'Hare, T.
    LEUKEMIA, 2015, 29 (09) : 1939 - 1942
  • [43] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
    Claudiani, Simone
    Apperley, Jane F.
    Khan, Afzal
    Khorashad, Jamshid
    Milojkovic, Dragana
    HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
  • [44] MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression
    Chen Huan
    Lou Jin
    Wang Heng
    An Na
    Pan Yuming
    Du Xin
    Zhang Qiaoxia
    LEUKEMIA RESEARCH, 2018, 75 : 1 - 6
  • [45] Distribution of BCR-ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
    Owojuyigbe, Temilola O.
    Durosinmi, Muheez A.
    Bolarinwa, Ramoni A. A.
    Salawu, Lateef
    Akinola, Norah O.
    Ademosun, Abdulwaheed A.
    Bosede, Oluwayomi T.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 646 - 651
  • [46] Detection of BCR-ABL1 tyrosine kinase domain mutations in chronic myeloidleukaemia patients with Imatinib resistance in Colombia
    Vasquez Palacio, Gonzalo
    Cecilia Ramirez, Gloria
    Enrique Muskus, Carlos
    Domingo Torres, Jose
    Alberto Aya, Carlos
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (01): : 8 - 17
  • [47] Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
    Razga, Filip
    Jurcek, Tomas
    Zackova, Daniela
    Dvorakova, Dana
    Toskova, Martina
    Jeziskova, Ivana
    Mayer, Jiri
    Racil, Zdenek
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 251 - 259
  • [48] Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
    Simona Soverini
    Elisabetta Abruzzese
    Monica Bocchia
    Massimiliano Bonifacio
    Sara Galimberti
    Antonella Gozzini
    Alessandra Iurlo
    Luigiana Luciano
    Patrizia Pregno
    Gianantonio Rosti
    Giuseppe Saglio
    Fabio Stagno
    Mario Tiribelli
    Paolo Vigneri
    Giovanni Barosi
    Massimo Breccia
    Journal of Hematology & Oncology, 12
  • [49] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [50] Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib
    Elnair, Radowan
    Galal, Ahmed
    BMC CANCER, 2018, 18
12345